OS, EFS, CI of CCyR, and c-CCyRS according to the molecular response to first-choice 2G-TKI at 3 months. The 77 patients who after 3 months of second-line therapy had BCR-ABL1/ABL1 ratios of ≤ 10% (solid line) had a significantly superior OS (A; 91.3% vs 72.1%, P = .02), EFS (B; 49.3% vs 13.0%, P < .001), and CI of CCyR (C; 76% vs 4%, P < .001) compared with the 30 patients with transcript ratios > 10% (broken line). Whiskers represent 95% confidence intervals. Ten patients had missing quantitative real-time PCR data and 2 were already receiving third-line TKI therapy and therefore were not included in the analysis. The patients with a transcript ratio ≤ 10% had a significantly higher probability of c-CCyRS (D; defined as the probability of being alive and in CCyR at a given time point): 67.2% for patients with a transcript level ≤ 10% (blue line) and 11.2% (P = .001) for patients with a higher transcript level (red line).